RVPH · Reviva Pharmaceuticals Holdings, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”View the 10-Q filed Aug 12, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent on equity repurchases (common and preferred combined, as reported) per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2020-11-30 YTD | $27,092,885 | 10-Q, filed 2021-01-14 |
| 2020-02-29 | $6,268,796 | 10-K, filed 2020-05-04 |